SCHEMBL29964992

SCHEMBL29964992

CN1CCc2cc(-c3cc(-c4ccc5c(c4)CCNC5=O)c(N)nc3F)ccc2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 7/20 0.43
PARP11 Q9NR21 7/20 0.43
MAPK1 P28482 1/20 0.43
MAPKAPK2 P49137 8/20 0.42
MAPK9 P45984 1/20 0.40
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
GSK3B P49841 1/20 0.38
CCNT1 O60563 1/20 0.37
CDK4 P11802 1/20 0.37
CCNA2 P20248 1/20 0.37
CCND1 P24385 1/20 0.37
CDK2 P24941 1/20 0.37
CCND3 P30281 1/20 0.37
CDK7 P50613 1/20 0.37
CDK9 P50750 1/20 0.37
CCNH P51946 1/20 0.37
MNAT1 P51948 1/20 0.37
CDK6 Q00534 1/20 0.37
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29964253 0.88 PARP10 (0.40) PARP10PARP11MAPK1MAPKAPK2MAPK9
SCHEMBL31079172 0.88 PARP10 (0.41) PARP10PARP11MAPK1MAPKAPK2MAPK9
SCHEMBL29964638 0.88 MAPKAPK2 (0.42) PARP10PARP11MAPK1MAPKAPK2MAPK9
SCHEMBL31079103 0.87 PARP10 (0.55) PARP10PARP11MAPK1MAPKAPK2MAPK9
SCHEMBL29964927 0.86 PARP10 (0.44) PARP10PARP11MAPK1MAPKAPK2MAPK9
SCHEMBL31079169 0.86 MAPK1 (0.43) PARP10PARP11MAPK1MAPKAPK2MAPK9
SCHEMBL29964207 0.86 MAPKAPK2 (0.40) PARP10PARP11MAPK1MAPKAPK2MAPK9
SCHEMBL31079179 0.85 PARP10 (0.44) PARP10PARP11MAPK1MAPKAPK2MAPK9
SCHEMBL29964678 0.85 MAPK1 (0.45) PARP10PARP11MAPK1MAPKAPK2MAPK9
SCHEMBL29964526 0.83 PARP10 (0.42) PARP10PARP11MAPK1MAPKAPK2MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-10-17 US disclosed
WO-2022226668-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) CMPK1, WNK1, AAK1 PARP10 2072/4885PARP11 1176/4885MAPK1 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.